Determinants and Monitoring of Response to disease-modifying therapy for Transthyretin Amyloidosis Cardiomyopathy: The ATTR-CM study

运甲状腺素蛋白淀粉样变性心肌病疾病缓解治疗反应的决定因素和监测：ATTR-CM 研究

• 批准号: 466555
• 负责人: Shahi Karan
• 金额: $ 1.27万
• 依托单位: University of Calgary
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466555&lang=en
• 关键词: Baseline Predictors Of Response; Cardiac Imaging; Evidence Based Approach; Heart Failure; Laboratory Biomarkers; Response To Therapy; Retrospective Cohort Study; Tafamidis Treatment/Therapy; Therapy Clinical Criteria; Transthyretin Amyloidosis Cardiomyopa

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a heart muscle disease with only a 3.6-year median survival time from diagnosis without treatment. ATTR-CM is caused by amyloid plaque buildup in the myocardial interstitium from misfolded transthyreti

甲状旁腺素淀粉样变性心肌病(ATTR-CM)是一种心肌疾病，从确诊到未经治疗的中位生存期只有3.6年。ATTR-CM是由错误折叠的跨甲状腺疾病所致的心肌间质淀粉样斑块积聚所致